CONCLUSION: Serum levels of IGF-I, IGF-II, and IGFBP-3 are not elevated in pancreatic cancer and do not appear to have a significant role in glucose homeostasis in this group of patients. BACKGROUND: The insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) have been implicated recently in the pathogenesis of pancreatic cancer, and increased serum levels of IGF-I or IGF-II have been reported previously in a number of other gastrointestinal malignancies. METHODS: Serum levels of IGF-I, IGF-II, and IGFBP-3 were measured by RIA in 20 patients with pancreatic cancer and 20 age-matched healthy control subjects and correlated with serum glucose, C-peptide, and glucose tolerance. RESULTS: No significant difference was observed in serum levels of IGF-I (13 vs 17 nmol/L, respectively), IGF-II (0.67 vs 0.91 U/mL), or IGFBP-3 (2.3 vs 2.3 mg/L) between the two groups of patients. Twelve (60%) patients had impaired glucose tolerance, but no correlation was observed between the serum levels of the IGFs and glucose tolerance.
CONCLUSION: Serum levels of IGF-I, IGF-II, and IGFBP-3 are not elevated in pancreatic cancer and do not appear to have a significant role in glucose homeostasis in this group of patients. BACKGROUND: The insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) have been implicated recently in the pathogenesis of pancreatic cancer, and increased serum levels of IGF-I or IGF-II have been reported previously in a number of other gastrointestinal malignancies. METHODS: Serum levels of IGF-I, IGF-II, and IGFBP-3 were measured by RIA in 20 patients with pancreatic cancer and 20 age-matched healthy control subjects and correlated with serum glucose, C-peptide, and glucose tolerance. RESULTS: No significant difference was observed in serum levels of IGF-I (13 vs 17 nmol/L, respectively), IGF-II (0.67 vs 0.91 U/mL), or IGFBP-3 (2.3 vs 2.3 mg/L) between the two groups of patients. Twelve (60%) patients had impaired glucose tolerance, but no correlation was observed between the serum levels of the IGFs and glucose tolerance.
Authors: J Zapf; C Schmid; H P Guler; M Waldvogel; C Hauri; E Futo; P Hossenlopp; M Binoux; E R Froesch Journal: J Clin Invest Date: 1990-09 Impact factor: 14.808
Authors: Y Nakanishi; J L Mulshine; P G Kasprzyk; R B Natale; R Maneckjee; I Avis; A M Treston; A F Gazdar; J D Minna; F Cuttitta Journal: J Clin Invest Date: 1988-07 Impact factor: 14.808
Authors: Hideo Suzuki; Yanan Li; Xiaoqun Dong; Manal M Hassan; James L Abbruzzese; Donghui Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-12 Impact factor: 4.254
Authors: S Rohrmann; V A Grote; S Becker; S Rinaldi; A Tjønneland; N Roswall; H Grønbæk; K Overvad; M C Boutron-Ruault; F Clavel-Chapelon; A Racine; B Teucher; H Boeing; D Drogan; V Dilis; P Lagiou; A Trichopoulou; D Palli; G Tagliabue; R Tumino; P Vineis; A Mattiello; L Rodríguez; E J Duell; E Molina-Montes; M Dorronsoro; J-M Huerta; E Ardanaz; S Jeurnink; P H M Peeters; B Lindkvist; D Johansen; M Sund; W Ye; K-T Khaw; N J Wareham; N E Allen; F L Crowe; V Fedirko; M Jenab; D S Michaud; T Norat; E Riboli; H B Bueno-de-Mesquita; R Kaaks Journal: Br J Cancer Date: 2012-02-07 Impact factor: 7.640
Authors: María José Ferri; Marc Saez; Joan Figueras; Esther Fort; Miriam Sabat; Santiago López-Ben; Rafael de Llorens; Rosa Núria Aleixandre; Rosa Peracaula Journal: PLoS One Date: 2016-01-25 Impact factor: 3.240